List of Excipients in Branded Drug SANNUO 5% MINOXIDIL HAIR GROWTH TREATMENT

Generic Drugs Containing SANNUO 5% MINOXIDIL HAIR GROWTH TREATMENT

Company	Ingredient	NDC	Excipient
Shenzhen Baixingchen Technology Co Ltd	hair growth spray	83648-003	ALCOHOL
Shenzhen Baixingchen Technology Co Ltd	hair growth spray	83648-003	PROPYLENE GLYCOL
Shenzhen Baixingchen Technology Co Ltd	hair growth spray	83648-003	WATER

What are the Most Frequently-Used Excipients in SANNUO 5% MINOXIDIL HAIR GROWTH TREATMENT?

# Of NDCs	Excipient
1	ALCOHOL
1	PROPYLENE GLYCOL
1	WATER

SANNUO 5% Minoxidil Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

SANNUO 5% Minoxidil Hair Growth Treatment competes in a mature OTC topical market where the active ingredient has limited differentiation. Commercial value is more likely to come from excipient selection, delivery format, tolerability, packaging, claims support, and channel positioning than from new minoxidil chemistry. The strongest opportunities are propylene-glycol-free liquid systems, low-irritation vehicles, foam or mousse formats, scalp-conditioning systems, and region-specific packaging and regulatory strategies.

This assessment treats SANNUO as a topical 5% minoxidil product. It does not assign unverified excipients to the product’s label.

What is the regulatory status of SANNUO 5% minoxidil?

5% topical minoxidil is an established OTC hair-growth product in the United States. FDA’s OTC framework permits minoxidil in topical products for the treatment of male pattern hair loss, subject to applicable active-ingredient, labeling, dosage-form, and safety requirements [1].

A product sold in the U.S. must generally follow one of three paths:

Regulatory route	Relevance to SANNUO
OTC monograph compliance	Primary route for a compliant topical minoxidil product
Approved NDA	Possible for a product with novel formulation, delivery technology, or claims requiring FDA review
ANDA	Relevant where the reference product and regulatory pathway support an abbreviated application

The U.S. market does not normally treat a monograph-compliant OTC minoxidil product like an NDA-listed prescription drug. That distinction affects Orange Book analysis, Paragraph IV litigation, and patent strategy.

What is the FDA status of 5% topical minoxidil?

FDA recognizes topical minoxidil as an OTC hair-growth active ingredient under the OTC drug framework. Product labeling must address intended use, application instructions, warnings, age restrictions, and the time required before results may appear [1].

The key commercial restrictions are:

• Treatment is directed to androgenetic alopecia or male pattern hair loss, depending on the labeling.
• The product must be applied to the scalp as directed.
• Continued use is generally required to maintain hair growth.
• Labels cannot freely expand into unsupported claims for alopecia areata, chemotherapy-related hair loss, or other conditions.
• Cosmetic claims about scalp feel, conditioning, reduced dryness, and appearance may be used only if they do not imply an unapproved therapeutic indication.

What excipients are typically used in 5% minoxidil products?

A conventional 5% minoxidil solution commonly uses ethanol, propylene glycol, purified water, and minoxidil. These ingredients create a solvent system capable of dissolving a relatively high concentration of minoxidil while supporting scalp application and evaporation.

What does each excipient contribute?

Excipient class	Commercial function	Main risk or limitation
Ethanol	Solvent, rapid evaporation, cooling sensation	Dryness, stinging, flammability
Propylene glycol	Solubilizer, humectant, penetration enhancer	Contact dermatitis and stickiness in sensitive users
Purified water	Vehicle and dilution medium	Can reduce solvent capacity and affect stability
Glycerin or other humectants	Moisture retention and reduced dry feel	Tackiness and slower drying
Surfactants or solubilizers	Support uniformity and delivery	Irritation, foaming, taste or odor concerns if poorly selected
Preservatives	Microbial control in water-containing systems	Sensitization and regulatory labeling burden
Conditioning polymers	Scalp feel, combability, film formation	Residue, buildup, compatibility problems
Fragrance	Consumer masking of ethanol or medicinal odor	Allergy and irritation concerns

The principal formulation challenge is maintaining minoxidil solubility without making the product excessively irritating, greasy, sticky, or slow to dry. A formula that reduces ethanol or propylene glycol must replace their solvent function or accept a lower concentration, a different dosage form, or a more complex delivery system.

What excipient strategy offers the greatest commercial opportunity?

The highest-value opportunity is a differentiated vehicle rather than a new active ingredient.

1. Propylene-glycol-free liquid

Propylene glycol is widely used in conventional minoxidil solutions, but some users report itching, scaling, burning, or dermatitis. A propylene-glycol-free product can target consumers who discontinue treatment because of scalp intolerance.

Possible strategies include:

• Ethanol-water systems with alternative solubilizers.
• Polyethylene glycol derivatives, subject to safety and compatibility assessment.
• Glycols with lower irritation profiles.
• Cyclodextrin-based solubilization.
• Solubilizing polymers or surfactant systems.
• Microemulsion or nanoemulsion systems.

The formulation must demonstrate chemical stability, dose uniformity, preservative effectiveness where applicable, and acceptable scalp tolerability. A simple substitution is unlikely to create durable IP protection unless the composition produces a measurable technical effect.

2. Low-odor and low-dryness solution

Consumers often object to the medicinal smell, rapid evaporation, alcohol dryness, and scalp tightness associated with minoxidil solutions. Commercial improvements could include:

• Lower-odor solvent blends.
• Controlled evaporation.
• Humectant combinations that reduce post-application dryness.
• Non-oily emollients at low concentrations.
• Fragrance-free and sensitive-scalp variants.
• Packaging that limits solvent loss after opening.

The strongest claims would relate to sensory performance, such as reduced residue, reduced odor, or improved scalp feel. Claims implying improved hair growth require clinical support.

3. Foam or mousse dosage form

Foam can improve cosmetic acceptance by reducing dripping and shortening perceived drying time. It also allows a product to avoid some of the characteristics associated with liquid solutions.

Foam-related excipient and packaging work may focus on:

• Propellant selection.
• Foam density and collapse time.
• Temperature sensitivity.
• Dose reproducibility.
• Valve and actuator design.
• Residue after drying.
• Scalp coverage with reduced runoff.

Foam products can support a premium price and subscription model, but they require more complex packaging, manufacturing controls, and transport analysis.

4. Scalp-conditioning system

A conditioning platform can position SANNUO above commodity products without changing the therapeutic active. Potential ingredients include panthenol, allantoin, niacinamide, selected amino acids, lightweight polymers, and carefully chosen humectants.

These ingredients may support cosmetic claims involving:

• Scalp moisturization.
• Reduced visible flaking caused by dryness.
• Improved softness.
• Improved combability.
• Reduced perception of irritation.
• Better application experience.

The company must avoid presenting cosmetic excipients as proven treatments for hair loss unless the claims are supported by appropriate evidence and permitted under the applicable regulatory pathway.

What formulations are protectable through excipient patents?

Patent protection is more credible when the excipient combination solves a defined technical problem and produces data that distinguish it from routine formulation work.

Potential patent claim categories

Claim category	Example protection target
Composition	5% minoxidil with defined solvent, solubilizer, humectant, and pH ranges
Dosage form	Stable foam, spray, gel, mousse, microemulsion, or film-forming solution
Performance	Reduced crystallization, improved deposition, controlled evaporation, reduced irritation
Packaging	Container-closure system that preserves solvent ratio and dose uniformity
Manufacturing	Mixing, cooling, filling, or crystallization-control process
Use	Treatment method using a specific excipient system or application schedule
Combination	Minoxidil with a scalp-conditioning or barrier-support composition

A composition patent is stronger when it includes narrow, non-obvious ranges and comparative data against conventional ethanol-propylene glycol systems. Broad claims covering “minoxidil and a solvent” are vulnerable to prior-art challenges because topical minoxidil formulations have been extensively commercialized.

What patent barriers affect a SANNUO launch?

The active ingredient itself is old and widely used. The main patent risks are therefore formulation-specific:

1. A third party may claim a particular foam composition.
2. A manufacturer may control a proprietary propellant or valve system.
3. A branded product may hold method-of-use claims tied to a specific delivery format.
4. A supplier may restrict access to a specialty solubilizer or polymer.
5. A formulation patent may be enforceable only in selected jurisdictions.

Freedom-to-operate analysis should separate active-ingredient claims from formulation, packaging, manufacturing, and use claims. Patent expiration dates must be checked claim by claim and jurisdiction by jurisdiction. A product should not be treated as clear merely because early minoxidil compound patents have expired.

Does SANNUO face Orange Book or Paragraph IV risk?

What is the Orange Book status of SANNUO?

A monograph-compliant OTC minoxidil product would not ordinarily depend on an Orange Book listing in the same way as an NDA-approved prescription product. Orange Book exposure becomes more relevant if SANNUO is tied to an approved NDA, an approved drug-device combination, or a product developed through an abbreviated approval pathway [2].

For a conventional OTC product, the more practical legal questions are:

• Whether the formulation infringes an active formulation patent.
• Whether the product uses a protected manufacturing process.
• Whether the labeling copies protected method-of-use language.
• Whether the product is marketed under a compliant OTC drug framework.
• Whether importation or private-label manufacturing creates additional exposure.

Which companies are challenging minoxidil exclusivity?

The minoxidil market is primarily challenged by generic OTC manufacturers, private-label retailers, contract manufacturers, and e-commerce brands. The competitive pressure is commercial rather than centered on a single current Paragraph IV event.

Paragraph IV litigation is more relevant to newer formulation technologies, prescription combinations, or NDA-backed products than to a standard OTC 5% minoxidil solution. A formulation owner should still monitor FDA patents, ANDA certifications, district court filings, and International Trade Commission proceedings where a protected dosage form or device is involved.

How strong is the patent estate for SANNUO 5% minoxidil?

The likely patent position of an undifferentiated 5% minoxidil solution is weak. The commercial product can still be attractive, but the moat would primarily come from:

• Brand recognition.
• Retail distribution.
• Low manufacturing cost.
• Customer retention.
• Product reviews and tolerability.
• Subscription fulfillment.
• Regional regulatory registrations.
• Proprietary packaging or differentiated dosage form.

Patent strength improves if SANNUO has a documented formulation platform with:

• A defined excipient ratio.
• Superior minoxidil solubility.
• Reduced precipitation during storage.
• Lower irritation in controlled testing.
• Improved scalp deposition.
• Better dose reproducibility.
• A non-obvious manufacturing process.
• Comparative data against leading 5% solutions.

A patent estate based only on adding a common humectant, fragrance, vitamin, or botanical ingredient would generally have limited defensive value unless the combination produces an unexpected technical result.

What commercial opportunities exist for SANNUO?

Which consumer segments are most attractive?

Segment	Product opportunity	Commercial rationale
Sensitive scalp users	Propylene-glycol-free, fragrance-free liquid	Addresses discontinuation from irritation
Premium users	Foam or mousse	Higher price and improved cosmetic experience
Women using topical minoxidil	Low-residue, low-odor format	Supports discreet daily use
Hair-care consumers	Minoxidil plus scalp-conditioning system	Links treatment with routine hair care
E-commerce subscribers	Refill bottles and subscription packs	Improves retention and recurring revenue
International markets	Region-specific labels and pack sizes	Expands beyond U.S. OTC positioning
Clinic and telehealth channels	Bundled treatment kits	Supports professional recommendation and adherence

The strongest near-term opportunity is a differentiated sensitive-scalp product with a clear propylene-glycol-free position. The most defensible premium opportunity is a foam or controlled-delivery format supported by formulation and packaging IP.

How can excipients increase revenue?

Excipients can support revenue through four mechanisms:

1. Premium pricing for improved tolerability or cosmetic feel.
2. Higher persistence because users are less likely to stop treatment.
3. Product-line extensions, including liquid, foam, travel, and sensitive-scalp versions.
4. Private-label licensing to retailers, telehealth companies, and dermatology platforms.

The commercial case should measure not only initial sales but also repeat purchase, treatment persistence, complaint rates, refund rates, and adverse-event reporting. A more expensive formula is justified only if it improves retention or supports a meaningful price premium.

How does SANNUO compare with conventional 5% minoxidil products?

Attribute	Conventional solution	Differentiated SANNUO opportunity
Active	5% minoxidil	Same active
Vehicle	Ethanol, propylene glycol, water	PG-free, low-irritation, or controlled-delivery system
Consumer experience	May feel wet, sticky, or drying	Faster drying and lower residue
Price	Commodity to mid-market	Mid-market to premium
IP position	Limited	Composition, process, packaging, or device claims
Channel	Mass retail and online	Specialty retail, dermatology, telehealth, subscription
Main risk	Price competition	Higher COGS and regulatory substantiation burden

What manufacturing and supply-chain barriers affect excipient strategy?

Alternative excipient systems can increase operational complexity. Key barriers include:

• Limited suppliers for pharmaceutical-grade solubilizers.
• Batch-to-batch variation in polymers and surfactants.
• Compatibility problems with pumps, valves, liners, and plastic bottles.
• Flammability controls for ethanol-rich systems.
• Foam filling and propellant infrastructure.
• Preservative effectiveness testing.
• Stability testing under accelerated and long-term conditions.
• Crystallization during shipping or temperature cycling.
• Regional restrictions on certain excipients or propellants.
• Higher minimum order quantities for specialty packaging.

A scalable formulation should be developed with at least two qualified suppliers for critical excipients where practical. The supply agreement should address change control, audit rights, specifications, impurity profiles, and notification periods.

What geographic opportunities exist for SANNUO?

The U.S. market offers a clear OTC framework but is highly price competitive. Europe, Canada, Australia, Southeast Asia, and Latin America each require separate assessment of drug classification, labeling, permitted excipients, advertising claims, and local registration.

Geographic expansion is more attractive when the product has a formulation advantage that travels across markets:

• Fragrance-free positioning for sensitive-scalp consumers.
• Climate-stable packaging for hot and humid markets.
• Smaller packs for price-sensitive markets.
• Foam or mousse for premium urban channels.
• Multilingual labels and localized application instructions.
• E-commerce fulfillment with region-specific regulatory controls.

The company should avoid treating one global formula and one global label as the default strategy. Minoxidil classification and advertising requirements can differ materially by jurisdiction.

Key Takeaways

• SANNUO’s strongest commercial path is excipient-led differentiation, not minoxidil novelty.
• A propylene-glycol-free 5% solution is the clearest tolerability opportunity.
• Foam, mousse, and controlled-delivery formats offer greater pricing power but require more complex manufacturing and packaging.
• The most valuable patents would cover defined excipient ranges, measurable stability or deposition benefits, dosage forms, packaging, and manufacturing processes.
• A standard OTC 5% minoxidil solution is likely to face intense generic and private-label competition.
• Orange Book and Paragraph IV issues are less central for a conventional monograph-compliant OTC product than formulation freedom-to-operate.
• Commercial success should be measured through repeat purchase, persistence, complaint rates, and channel retention, not initial unit sales alone.
• Geographic expansion requires jurisdiction-specific classification, excipient, labeling, and claims analysis.

FAQs

Can SANNUO use a propylene-glycol-free formulation without changing the 5% minoxidil strength?

Yes. The product can retain 5% minoxidil if the alternative vehicle maintains solubility, stability, uniformity, and acceptable performance throughout shelf life. The substitute system requires formulation and regulatory testing.

Is a minoxidil foam easier to patent than a minoxidil liquid?

Usually, a foam may offer more claimable technical elements, including composition, foam properties, propellant selection, valve design, and manufacturing controls. Patent strength still depends on novelty, non-obviousness, enablement, and prior art.

Can SANNUO add biotin, caffeine, or botanical ingredients to improve marketability?

It can add cosmetic or supportive ingredients if the finished product remains safe, stable, properly labeled, and compliant with applicable claims rules. Those ingredients do not automatically establish clinical efficacy for hair regrowth.

What is the most defensible premium claim for an excipient-driven minoxidil product?

Claims involving reduced residue, improved scalp feel, fragrance-free use, propylene-glycol-free composition, or faster drying are generally more defensible than unsupported claims of superior hair growth.

Can SANNUO license its excipient technology to other brands?

Yes. A validated formulation platform could be licensed to retailers, telehealth providers, dermatology companies, and regional pharmaceutical marketers. The license should define territory, dosage form, regulatory responsibility, manufacturing rights, improvements, and ownership of formulation data.

References

1. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 341: Skin protectant drug products for over-the-counter human use and related OTC drug monograph provisions. Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: A review. Drug Design, Development and Therapy, 13, 2777-2786.

4. Messenger, A. G., & Rundegren, J. (2004). Minoxidil: Mechanisms of action on hair growth. British Journal of Dermatology, 150(2), 186-194.

5. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Public Search. U.S. Department of Commerce.